Razadyne

Janssen Pharmaceuticals, the pharmaceutical division of Johnson & Johnson, is a global leader in the development and commercialization of innovative medicines across several therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. The company is responsible for the commercialization of Razadyne (galantamine), a widely used treatment for mild to moderate Alzheimer's disease that functions as an acetylcholinesterase inhibitor and nicotinic receptor modulator. Janssen's extensive portfolio includes blockbuster therapies such as Stelara, Tremfya, and Darzalex, alongside a robust pipeline of next-generation biologics and small molecules. Headquartered in Beerse, Belgium, and Titusville, New Jersey, the company leverages significant R&D investment to address high unmet medical needs worldwide. Janssen operates as a core pillar of Johnson & Johnson's healthcare strategy, focusing on transformative medical breakthroughs and global health equity.